KZIA

Kazia Therapeutics Limited ADR

8.50

Oct 30 • 3:59 PM ET -0.22 (-2.52%)

8.50

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology Australia Micro NASD

Peers: NTHI MBRX CRDF ONCY BOLD IMMP ACTU ATHE SLXN DRTS

| Held by: APIE

Scroll to Statements

Index	-
Market Cap	97.16M
Enterprise Value	50.90M
Income	-14.73M
Sales	0.03M
Book/sh	2.73
Cash/sh	4.05
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Jan 06, 1999

P/E	-
Forward P/E	-
PEG	-
P/S	3238.50
P/B	3.11
P/C	2.10
P/FCF	-
EV/EBITDA	-
EV/Sales	1696.83
Quick Ratio	2.87
Current Ratio	2.87
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-6.82
EPS next Y	-1.42
EPS next Q	-0.07
EPS this Y	23.08%
EPS next Y	-56.41%
EPS next 5Y	-10.60%
EPS past 3/5Y	43.68% 25.92%
Sales past 3/5Y	- -
EPS Y/Y TTM	76.83%
Sales Y/Y TTM	-98.25%
EPS Q/Q	67.55%
Sales Q/Q	-
Earnings	Sep 04
EPS/Sales Surpr.	0.00% 0.00%

Insider Own	14.01%
Insider Trans	0.00%
Inst Own	41.39%
Inst Trans	16.36%
ROA	-50.34%
ROE	-102.88%
ROIC	-47.53%
Gross Margin	-
Oper. Margin	-49070.50%
Profit Margin	-55271.07%
SMA20	2.83%
SMA50	-16.92%
SMA200	-19.39%
Trades

Shs Outstand	11.34M
Shs Float	9.83M
Short Float	13.31%
Short Ratio	4.79
Short Interest	1.31M
52W High	17.40 -51.15%
52W Low	4.86 74.90%
Volatility	7.95% 8.47%
ATR (14)	0.72
RSI (14)	46.23
Beta	2.35
Rel Volume	0.84
Avg Volume	273.09K
Volume	230,442

Perf Week	8.83%
Perf Month	-10.24%
Perf Quarter	-31.51%
Perf Half Y	-36.52%
Perf YTD	23.37%
Perf Year	10.68%
Perf 3Y	-67.92%
Perf 5Y	-98.43%
Perf 10Y	-97.20%
Recom	1.00
Target Price	31.14
Prev Close	8.72
Price	8.50
Change %	-2.52%

Consensus

Strong Buy

Avg. Price Target

$31.14

Implied Upside

+266.4%

Analysts9incl. previous ratings

Rating Distribution9 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 30, 2026	Initiated	NNeedham	Buy	$27	+217.6%
Oct 21, 2026	Initiated	GGuggenheim	Buy	$35	+311.8%
Oct 20, 2026	Initiated	LLeerink Partners	Outperform	$30	+252.9%
Aug 13, 2026	Initiated	CCanaccord Genuity	Buy	$29	+241.2%
Jul 01, 2026	Initiated	BBTIG Research	Buy	$34	+300.0%
Jun 11, 2026	Initiated	LLake Street	Buy	$32	+276.5%
Apr 15, 2026	Initiated	LLaidlaw	Buy	$25	+194.1%
Feb 06, 2025	Initiated	MMaxim Group	Buy	$3	-64.7%
Oct 14, 2021	Initiated	MMaxim Group	Buy	$18	+111.8%
Jan 05, 2021	Initiated	HH.C. Wainwright	Buy	$17	+100.0%

Oct-29-26 07:00AM	Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference (PR Newswire)
Sep-22-26 07:30AM	Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders (PR Newswire)
Sep-09-26 07:30AM	Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer (PR Newswire)
Sep-01-26 07:30AM	Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy (PR Newswire) -8.28%
07:15AM	Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer (PR Newswire)
05:52AM	Loading…
05:52AM	Kazia closes oversubscribed offering to fund paxalisibs clinical development (Pharmaceutical Technology)
Aug-31-26 05:58PM	Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering (PR Newswire)
Aug-28-26 07:30AM	Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering (PR Newswire) -19.64%
Aug-27-26 04:09PM	Kazia Therapeutics Limited Announces Proposed Public Offering (PR Newswire) +15.75%
04:01PM	Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer (PR Newswire)
Jun-02-26 07:30AM	Kazia Therapeutics Appoints James Levine as Chief Financial Officer (PR Newswire) -6.13%
May-26-26 07:30AM	Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer (PR Newswire) -8.42%
Apr-15-26 08:00AM	Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform (PR Newswire) +5.71%
Apr-13-26 05:05PM	Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform (PR Newswire) +5.23%
Jan-30-26 08:00AM	Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) (PR Newswire)
12:51PM	Loading…
Jan-27-26 12:51PM	Kazia Therapeutics Reports Positive Early Responses In Aggressive Breast Cancer Trial (Benzinga) -9.84%
08:00AM	Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer (PR Newswire)
Jan-08-26 09:00AM	Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End (PR Newswire)
Jan-07-26 10:32AM	How $594B in Precision Tech is Cracking the Metastatic Cancer Code (PR Newswire)
Dec-22-25 08:00AM	Kazia Therapeutics Regains Full Nasdaq Listing Compliance (PR Newswire) -8.00%
Dec-10-25 08:00AM	Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+ (PR Newswire) -17.79%
Dec-02-25 09:00AM	Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities (PR Newswire) +9.95%
Nov-18-25 04:15PM	Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy (PR Newswire) -5.29% +34.37%
Oct-27-25 07:15AM	Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner (PR Newswire)
Oct-07-25 08:30AM	Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program (PR Newswire) +5.31%
Oct-02-25 08:30AM	Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen (PR Newswire) -7.88%
Oct-01-25 09:21AM	Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG (PR Newswire)
Sep-11-25 08:00AM	Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy (PR Newswire)
Aug-01-25 08:00AM	Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market (PR Newswire)
Jul-10-25 09:20AM	Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up (PR Newswire) +8.71%
02:47PM	Loading…
Jul-09-25 02:47PM	Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps (Benzinga) +39.63%
08:00AM	Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial (PR Newswire)
Jun-11-25 08:00AM	Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC) (PR Newswire) +81.53%
Jun-05-25 08:00AM	Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer (PR Newswire)
May-15-25 08:00AM	Kazia Therapeutics Highlights Recent Progress and Provides Business Update (PR Newswire) -6.51%
Mar-31-25 07:30AM	Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil (PR Newswire) -11.04%
Feb-20-25 08:46AM	Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease (PR Newswire)
Jan-31-25 07:29AM	Is Kazia Therapeutics (KZIA) One of the Best ASX Stocks to Buy According to Hedge Funds? (Insider Monkey) -16.84%
Jan-30-25 07:30AM	Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer (PR Newswire) +37.68%
Jan-27-25 08:00AM	Why Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now? (Insider Monkey) -8.82%
Jan-14-25 04:00PM	Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering (PR Newswire)
Jan-11-25 10:05AM	Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering (TipRanks)
Jan-10-25 09:58AM	Kazia Therapeutics Announces $2.0 Million Registered Direct Offering (PR Newswire) -6.51%
Dec-31-24 12:34PM	Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday? (Benzinga) -42.90%
08:00AM	Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA (PR Newswire)
Dec-11-24 08:00AM	Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium (PR Newswire)
Nov-04-24 07:30AM	Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme (PR Newswire) +19.20%
Oct-16-24 07:27AM	Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing (TipRanks)
Oct-15-24 07:32AM	Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women (PR Newswire) -18.01%
Oct-02-24 08:45AM	Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting (PR Newswire)
Sep-23-24 08:30AM	Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium (PR Newswire)
Sep-12-24 07:30AM	KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER (PR Newswire) -5.25%
Jul-31-24 09:53AM	7 Top Stocks Under $10: July 2024 Edition (InvestorPlace)
07:00AM	Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making? (InvestorPlace)
Jul-25-24 06:10AM	Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics (InvestorPlace) +15.59%
Jul-12-24 11:24AM	Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why (Zacks) -27.76%
10:08AM	From Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode Higher (InvestorPlace)
07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jul-11-24 01:26PM	Silk Recalls 2024: What to Know as Plant-Based Milk Recalled Over Listeria Concerns (InvestorPlace) +85.57%
01:01PM	FCEL Stock Alert: FuelCell Energy Pops on Korean Market Update (InvestorPlace)
12:51PM	JOBY Stock Pops After Completing 523-Mile eVTOL Flight (InvestorPlace)
12:31PM	KZIA Stock Alert: Kazia Continues Its Surge on Thursday With 51% Gains (InvestorPlace)
07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
06:32AM	Kazia Therapeutics stocks soar following Phase II/III win (Clinical Trials Arena)
Jul-10-24 12:42PM	KBW Just Cut Its Price Target on SoFi (SOFI) Stock (InvestorPlace) +248.02%
12:08PM	PLUG Stock: Plug Power Shares Hydrogen Refueling Station Update (InvestorPlace)
11:57AM	Why Is Kazia Therapeutics (KZIA) Stock Up 300% Today? (InvestorPlace)
07:30AM	Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma (PR Newswire)
Jun-27-24 08:15AM	KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER (PR Newswire) +6.37%
May-23-24 02:41PM	Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement (PR Newswire)
May-21-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
May-02-24 04:22AM	Kazia concludes first stage of Phase I advanced cancer treatment trial (Clinical Trials Arena) -5.42%
May-01-24 08:45AM	KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS (PR Newswire) -10.78%
Mar-24-24 07:55AM	11 Best ASX Stocks To Buy Now (Insider Monkey)
Mar-21-24 08:52AM	Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases (PR Newswire) -8.89%
Mar-13-24 08:00AM	Kazia announces presentation of new data at AACR Annual Meeting (PR Newswire) +8.36%
Feb-21-24 07:30AM	Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint (PR Newswire) -20.61%
Jan-18-24 07:30AM	KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS (PR Newswire)
Dec-05-23 06:02PM	Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering (PR Newswire)
Dec-01-23 08:00AM	Kazia Therapeutics Announces $2 Million Registered Direct Offering (PR Newswire) -19.56%
Nov-29-23 07:01AM	KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY (PR Newswire) -6.34%
Nov-21-23 07:30AM	KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING (PR Newswire) -10.59%
Nov-20-23 04:30PM	KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION (PR Newswire) -6.11%
Nov-15-23 08:30AM	KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING (PR Newswire)
Nov-10-23 07:01AM	KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA (PR Newswire)
Nov-01-23 07:01AM	KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA (PR Newswire)
Oct-23-23 07:01AM	KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY (PR Newswire) -5.29%
Oct-11-23 07:01AM	Kazia announces voluntary delisting from ASX (PR Newswire) -15.78%
Oct-05-23 07:01AM	KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS (PR Newswire)
Sep-29-23 07:01AM	KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING (PR Newswire) -5.21%
Jul-06-23 07:00AM	KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY (PR Newswire) -8.55%
Jun-08-23 07:00AM	KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA (PR Newswire)
May-25-23 07:01AM	KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT (PR Newswire)
Apr-14-23 07:01AM	KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT (PR Newswire) +9.09%
Apr-04-23 07:00AM	KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING (PR Newswire) +6.86%
Jan-25-23 03:03PM	Trade Alert: Stephen Abolakian At Kazia Therapeutics Limited (ASX:KZA), Has Just Spent AU$1m Buying 54% More Shares (Simply Wall St.) -5.81%
Jan-18-23 11:50AM	Kazia Therapeutics CEO talks $4.5 million capital raise (News Direct) +5.28%
Jan-16-23 07:01AM	KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS (PR Newswire)
Dec-19-22 09:00PM	Kazia Therapeutics (KZIA): Collaboration May Expand Utility to Combo Therapies (ACCESSWIRE)
Dec-15-22 07:01AM	KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING (PR Newswire)

Show Previous News

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

M.D.Dr. John Edwin Friend II

B.Com.Ms. Elissa C. Hansen ACSA

VP of Finance & ControllerMr. Jeffrey Bonacorda

Chief Financial OfficerMr. James E. Levine

Chief Scientific OfficerDr. Sudha Rao

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KZIA

Kazia Therapeutics Limited ADR

Upgrade your Finviz experience